Hua Liang

发表

AWARD NUMBER: W81XWH-17-C-0153 TITLE: Developing software for Pharmacodynamics and Bioassay Studies PRINCIPAL INVESTIGATOR: Hua Liang CONTRACTING ORGANIZATION: TCONNEX Inc

Larry Z. Liu, Hua Liang, 2018 .

Analysis of Relation between Virologic Responses and Immunologic Responses, Patient's Factors in AIDS Clinical Trials Using – A Semiparametric Mixed‐Effects Model

Guohua Zou, Hua Liang, 2007, Biometrical journal. Biometrische Zeitschrift.

Characterization of PD-L1 expression and its prognostic value in patients with ovarian cancer

Gao-Hua Wang, Hua Liang, Jian-hua Chen, 2018, Translational Cancer Research.

Comparison of antitumor activities in tumor xenograft treatment.

Hua Liang, 2007, Contemporary clinical trials.

Analyzing the detrimental effects of female chronic hepatitis B virus DNA on ovarian reserve function and results of in vitro fertilization

J. Yang, Hua Liang, Wei Li, 2022, Clinical and Experimental Obstetrics & Gynecology.

Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models

M. Bjornsti, P. Houghton, J. Peterson, 2005, Cancer Chemotherapy and Pharmacology.

Comprehensive analysis of temozolomide treatment for patients with glioma.

Wenbing Yang, Hua Liang, B. Xing, 2014, Asian Pacific journal of cancer prevention : APJCP.

Force of tuberculosis infection among adolescents in a high HIV and TB prevalence community: a cross-sectional observation study

L. Myer, L. Bekker, R. Wood, 2011, BMC infectious diseases.

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

A. Antinori, A. De Luca, C. Mussini, 2011, BMC infectious diseases.

A new method of evaluating antitumor activity from measured tumor volumes.

Hua Liang, 2006, Contemporary clinical trials.